Treatment
Tumor Infiltrating Lymphocyte clinical trials
We’re tracking 44 recruiting studies that include Tumor Infiltrating Lymphocyte, each written for real people, not researchers, below.
Recruiting studies
- NCT06453057Recruiting
TIL therapy for ovarian cancer
This trial tests a new therapy made from your own immune cells (called TILs) to fight ovarian cancer. Doctors remove some of your tumor, grow the immune cells in a lab, and then give them back to you to attack the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06783270RecruitingPhase 1
T-Cell Therapy for Advanced Melanoma
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
Herlev, Capital RegionAges 18–75 - NCT06819280Recruiting
Immune cells for advanced colorectal cancer after first treatment
This trial tests whether your own immune cells, called tumor-infiltrating lymphocytes (TILs), can be grown in a lab and given back to you to fight advanced colorectal cancer. It is for people whose cancer has continued to grow after their first round of chemotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07560111RecruitingPhase 2
GC101 cell therapy for advanced lung cancer
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
ShanghaiAges 18–70 - NCT06473961RecruitingPhase 1
GC101 cell therapy for advanced non-small cell lung cancer
This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.
ShanghaiAges 18–70 - NCT04943913RecruitingEarly Phase 1
TIL cell therapy for brain glioma after standard treatment fails
This early-stage study tests a treatment made from your tumor’s immune cells (TILs) to help shrink brain glioma. You may be considered if your glioma is back or has spread and standard options are no longer working (or don’t exist).
Suzhou, JiangsuAges 18–75 - NCT05142475RecruitingEarly Phase 1
Study of GC101 tumor-infiltrating cells for advanced breast cancer
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
ShanghaiAges 18–75 - NCT06455917RecruitingPhase 2
Personalized immune cell therapy for advanced lung cancer
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
Basel, Canton of Basel-CityAges 18 years+ - NCT06476119Recruiting
Optimizing treatment for low stage triple-negative breast cancer with high immune cells
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Sittard-Geleen, LimburgAges 18 years+ - NCT06481592RecruitingPhase 2
Study of lifileucel for advanced endometrial cancer
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Phoenix, ArizonaAges 18–70 - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT06532812RecruitingPhase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer
This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.
Beijing, Beijing MunicipalityAges 16–90 - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT06828328RecruitingEarly Phase 1
Gene-edited TIL therapy for pancreatic cancer
This trial tests a new treatment called GC203 TIL, which uses your own immune cells (TILs) that have been gene-edited to fight pancreatic cancer. It is for people whose cancer has not responded to standard treatments and who are healthy enough to undergo this therapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT01174121RecruitingPhase 2
Immunotherapy made from your tumor-fighting immune cells
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.
Bethesda, MarylandAges 18–72 - NCT02621021RecruitingPhase 2
Metastatic melanoma trial using immune cells plus IL-2
This Phase 2 study tests a form of immune cell therapy for metastatic melanoma, using tumor-infiltrating lymphocytes (TIL) and IL-2. Some people also may receive pembrolizumab, and the goal is to see if this approach can shrink the cancer.
Bethesda, MarylandAges 18–72 - NCT06470607Recruiting
Lung tumor immune cell study for surgery patients
This study looks at immune cells inside lung tumors to better understand how they work. If you are having surgery for a thoracic tumor, your tissue could help researchers learn more.
MilanAges 18 years+ - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06006390RecruitingPhase 1/Phase 2
CAR-T therapy for CEA-positive advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
Taiyuan, ShanxiAges 18 years+
Common questions
- Are there clinical trials studying Tumor Infiltrating Lymphocyte?
- Yes. Clin2 currently lists 44 recruiting studies that include Tumor Infiltrating Lymphocyte, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tumor Infiltrating Lymphocyte trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tumor Infiltrating Lymphocyte an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tumor Infiltrating Lymphocyte or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.